Literature DB >> 27387345

Level of Discomfort Decreases After the Administration of Continuous Palliative Sedation: A Prospective Multicenter Study in Hospices and Palliative Care Units.

Rogier H P D van Deijck1, Jeroen G J Hasselaar2, Stans C A H H V M Verhagen2, Kris C P Vissers2, Raymond T C M Koopmans3.   

Abstract

CONTEXT: A gold standard or validated tool for monitoring the level of discomfort during continuous palliative sedation (CPS) is lacking. Therefore, little is known about the course of discomfort in sedated patients, the efficacy of CPS, and the determinants of discomfort during CPS.
OBJECTIVES: To identify the course of discomfort in patients receiving CPS.
METHODS: A prospective observational multicenter study in nine hospices and palliative care units was performed. The Discomfort Scale-Dementia of Alzheimer Type (DS-DAT) was independently assessed for monitoring of patient discomfort during CPS. The DS-DAT scores range from 0 (no observed discomfort) to a maximum of 27 (high level of observed discomfort). Using a mixed model, the mean group score of discomfort between four predefined time frames of CPS was compared, correcting for confounding patient characteristics.
RESULTS: A total of 130 patients were sedated, and the DS-DAT was completed in 106 patients at least once. The median duration of the sedation in these 106 patients was 25.5 hours (range 2-161). The mean score of the DS-DAT in the phase before sedation was 12.16 (95% CI 9.83-14.50) and decreased significantly to 8.06 (95% CI 5.53-10.58) in the titration phase of sedation. The mean score of the DS-DAT in the final phase of sedation was 7.42 (95% CI 4.90-9.94).
CONCLUSION: This study shows that CPS is associated with a decrease in the level of discomfort within an acceptable time frame, although in some sedated patients higher levels of discomfort in the last hours of life occurred. Although the DS-DAT seems to be of value for monitoring the level of discomfort during CPS, the results of this study should be interpreted within the constraints of the limitations, and further research on the psychometric properties of this tool is needed before the DS-DAT can be used in clinical practice.
Copyright © 2016 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Discomfort; hospices; nursing home-based palliative care units; palliative sedation

Mesh:

Substances:

Year:  2016        PMID: 27387345     DOI: 10.1016/j.jpainsymman.2016.05.008

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  6 in total

1.  [Palliative sedation : Development and consensus of a German language documentation template].

Authors:  C Klein; C Wittmann; K N Wendt; C Ostgathe; S Stiel
Journal:  Anaesthesist       Date:  2018-07       Impact factor: 1.041

2.  Reflections on palliative sedation.

Authors:  Robert Twycross
Journal:  Palliat Care       Date:  2019-01-27

3.  European Palliative Sedation Project.

Authors:  Sheila A Payne; Jeroen Hasselaar
Journal:  J Palliat Med       Date:  2020-02       Impact factor: 2.947

Review 4.  How to measure the effects and potential adverse events of palliative sedation? An integrative review.

Authors:  Alazne Belar; María Arantzamendi; Sheila Payne; Nancy Preston; Maaike Rijpstra; Jeroen Hasselaar; Lukas Radbruch; Michael Vanderelst; Julie Ling; Carlos Centeno
Journal:  Palliat Med       Date:  2020-12-14       Impact factor: 4.762

5.  Association of the RASS Score with Intensity of Symptoms, Discomfort, and Communication Capacity in Terminally Ill Cancer Patients Receiving Palliative Sedation: Is RASS an Appropriate Outcome Measure?

Authors:  Kengo Imai; Tatsuya Morita; Naosuke Yokomichi; Masanori Mori; Akemi Shirado Naito; Toshihiro Yamauchi; Hiroaki Tsukuura; Yu Uneno; Satoru Tsuneto; Satoshi Inoue
Journal:  Palliat Med Rep       Date:  2022-04-08

Review 6.  The Decision-Making Process for Palliative Sedation for Patients with Advanced Cancer-Analysis from a Systematic Review of Prospective Studies.

Authors:  Alazne Belar; Maria Arantzamendi; Johan Menten; Sheila Payne; Jeroen Hasselaar; Carlos Centeno
Journal:  Cancers (Basel)       Date:  2022-01-08       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.